A Risk Stratification Model for Predicting Benefits of Intensive Blood Pressure Treatment: Analysis of the Systolic Blood Pressure Intervention Trial
The Journal of Clinical Hypertension · 2025
DOI: 10.1111/jch.70098 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift The Journal of Clinical Hypertension, 2025. Verfasst von Na Li und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Health Care (Geriatrics), China-Japan Friendship Hospital, Ministry of Health, Beijing, China. Hauptthemen laut MEDLINE: Hypertension, Antihypertensive Agents, Blood Pressure. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Capital Health Development Scientific Research Project, Research Center for the development of Medical Science and Technology, National Health Commission of the People's Republic of China.
Abstract (Originalsprache)
Current hypertension guidelines lack personalized strategies for blood pressure control. While the Systolic Blood Pressure Intervention Trial (SPRINT) demonstrated benefits of intensive blood pressure lowering, identifying optimal candidates for such treatment remains challenging. We developed and validated a risk stratification model using data from 9139 SPRINT participants. The model incorporated 11 clinical variables through multivariable Cox regression analysis. Patients were stratified into low‐, medium‐, and high‐risk groups. The study protocol was registered at ClinicalTrials.gov (NCT01206062). The model showed good discrimination with C‐indices of 0.7354 (95% CI: 0.7065–0.7710) and 0.6894 (95% CI: 0.6545–0.7266) at 3 years for training and validation sets, respectively. Intensive treatment significantly reduced cardiovascular events in medium‐risk (3.17% vs. 5.11%, p = 0.0376) and high‐risk groups (9.34% vs. 11.86%, p = 0.0269), while showing a nonsignificant trend in the low‐risk group (2.87% vs. 3.34%, p = 0.0870). The Rank‐Weighted Average Treatment Effect analysis (16.06) supported potential benefits from individualized treatment allocation. No increased risk of severe adverse events was observed across risk groups. Our risk stratification model effectively identifies patients who derive significant cardiovascular benefits from intensive blood pressure lowering, particularly in medium‐ and high‐risk groups. This approach could guide more personalized hypertension management strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Health Care (Geriatrics), China-Japan Friendship Hospital, Ministry of Health, Beijing, China.
- Department of Mathematical Sciences, Ball State University, Muncie, Indiana, USA.
- Department of Information System and Operations Management, Ball State University, Muncie, Indiana, USA.
- Centre of Hypertension, Beijing Anzhen Hospital, Capital Medical University, Beijing, China.
ORCID-Profile: Wenli Cheng
Förderung
- Capital Health Development Scientific Research Project
- Research Center for the development of Medical Science and Technology
- National Health Commission of the People's Republic of China
Zitieren
APA
Li, N., Yang, Z., Yuan, Q., & Cheng, W. (2025). A Risk Stratification Model for Predicting Benefits of Intensive Blood Pressure Treatment: Analysis of the Systolic Blood Pressure Intervention Trial. The Journal of Clinical Hypertension. https://doi.org/10.1111/jch.70098
Vancouver
Li N, Yang Z, Yuan Q, Cheng W. A Risk Stratification Model for Predicting Benefits of Intensive Blood Pressure Treatment: Analysis of the Systolic Blood Pressure Intervention Trial. The Journal of Clinical Hypertension. 2025. doi:10.1111/jch.70098
BibTeX
@article{Li2025,
author = {Li, Na and Yang, Zhixin and Yuan, Quan and Cheng, Wenli},
title = {A Risk Stratification Model for Predicting Benefits of Intensive Blood Pressure Treatment: Analysis of the Systolic Blood Pressure Intervention Trial},
journal = {The Journal of Clinical Hypertension},
year = {2025},
doi = {10.1111/jch.70098}
}
EUVIMED